Category: Conferences
Search News
Coming together to tackle pancreatic cancer – The London Pancreas Workshop
29th June 2023
Experts in the field converged to discuss the latest advances in pancreatic cancer
Read more
Clinical trial shows tumour-starving drug improves survival of mesothelioma
16th April 2023
An innovative therapy provides new hope to patients with malignant mesothelioma – a rare but rapidly fatal type of cancer with few effective treatment options – according to results presented by Professor Peter Szlosarek and his team at Barts Cancer Institute, Queen Mary University of London.
Read more
Blood test predicts chemotherapy resistance in prostate cancer
11th November 2021
Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.
Read more
New class of drug reduces risk of death in bladder cancer
15th February 2021
A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Professor Tom Powles from Barts Cancer Institute, Queen Mary University of London and Barts Health NHS Trust.
Read more
London Pancreas Workshop 2020
30th September 2020
On 11th September 2020, Professors Hemant Kocher and Nick Lemoine hosted the eighth London Pancreas Workshop (LPW) – a forum for state-of-the-art clinical and basic research in pancreatic cancer. In a first for the biennial event, this year’s LPW took place online with pre-recorded speaker presentations and live, interactive Q&A sessions.
Read more
Immunotherapy for advanced bladder cancer
29th May 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more